Negative symptoms and neuroleptics in catatonic schizophrenia

Schizophrenia Research

Volumn 59, Issue 1, 2003, Pages 73-76

  Salokangas, Raimo K R ^a   Honkonen, Teija ^c   Stengård, Eija ^d   Koivisto, Anna Maija ^e   Hietala, Jarmo ^a,b,f  

^a UNIVERSITY OF TURKU   (Finland)

^b Turku Psychiatric Clinic   (Finland)

^c FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e UNIVERSITY OF TAMPERE   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Catatonia; Dopaminergic pathway; Negative symptoms; Neuroleptic medication; Schizophrenia

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CATATONIC SCHIZOPHRENIA; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; RATING SCALE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIA, CATATONIC; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0037209947     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00155-X     Document Type: Article

References (17)

1. Black K.J., Gado M.H., Perlmutter J.S. PET measurement of dopamine D2 receptor-mediated changes in striatopallidal function. Journal of Neuroscience. 17:1997;3168-3177.
2. Blumer D. Catatonia and neuroleptics: psychobiologic significance of remote and recent findings. Comprehensive Psychiatry. 38:1997;193-201.
3. Bodkin J.A., Cohen B.M., Salomon M.S., Cannon S.E., Zornberg G.L., Cole J.O. Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. Journal of Nervous and Mental Diseases. 184:1996;295-301.
4. Carpenter W.T. Jr., Heinrichs D.W., Wagman A.M.I. Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry. 145:1988;578-583.
5. Clark T., Rickards H. Catatonia: 2. Diagnosis, management and prognosis. Hospital Medicine. 60:1999;812-814.
6. Crow T.J. The two syndrome concept: origins and current status. Schizophrenia Bulletin. 11:1985;471-485.
7. Dao-Castellana M.H., Paillere-Martinot M.-L., Hantraye P., Attar-Levy D., Remy P., Crouzel C., Artiges E., Feline A., Syrota A., Martinot J.L. Presynaptic dopaminergic function of schizophrenic patients. Schizophrenia Research. 23:1997;167-174.
8. Glenberg A.J. Catatonic reaction to high-potency neuroleptic drugs. Archives of General Psychiatry. 34:1977;947-950.
9. Hietala J., Syvälahti E., Vuorio K.et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 346:1995;1130-1131.
10. Johnson J. Catatonia: the tension insanity. British Journal of Psychiatry. 162:1993;733-738.
11. Kay S.R., Opler L.A., Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Rating Manual. 1986;Bronx Psychiatric Center, Bronx.
12. Liddle P.F. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. British Journal of Psychiatry. 151:1987;145-151.
13. Lindenmayer J.P., Bernstein-Hyman R., Crochowski S. Five factor model of schizophrenia: initial validation. Journal of Nervous and Mental Diseases. 182:1994;631-638.
14. McGlashan T.H., Fenton W.S. Classical subtypes for schizophrenia: literature review for DSM-IV. Schizophrenia Bulletin. 17:1991;609-632.
15. Salokangas R.K.R. Structure of schizophrenic symptomatology and its changes over time: prospective factor-analytic study. Acta Psychiatrica Scandinavica. 195:1997;32-39.
16. Salokangas R.K.R., Saarinen S. Deinstitutionalisation and schizophrenia in Finland: discharged patients and their care. A follow-up study of schizophrenic patients discharged from Finnish mental hospitals in 1982, 1986 and 1990. Schizophrenia Bulletin. 24:1998;457-467.
17. Salokangas R.K.R., Honkonen T., Stengård E., Koivisto A-M. Symptom dimensions and their association with outcome and treatment settings in long-term schizophrenia. Results of the DSP project. Nordic Journal of Psychiatry. 2002;. in press.